+关注
WilliamWCW
暂无个人介绍
IP属地：未知
7
关注
0
粉丝
0
主题
0
勋章
主贴
热门
WilliamWCW
2021-06-18
👍
ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573693462129192","uuid":"3573693462129192","gmtCreate":1610613529700,"gmtModify":1610613529700,"name":"WilliamWCW","pinyin":"williamwcw","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":168300830,"gmtCreate":1623948538020,"gmtModify":1634025353021,"author":{"id":"3573693462129192","authorId":"3573693462129192","name":"WilliamWCW","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573693462129192","authorIdStr":"3573693462129192"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168300830","repostId":"1103057922","repostType":2,"repost":{"id":"1103057922","kind":"news","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company <b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8 <a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":168300830,"gmtCreate":1623948538020,"gmtModify":1634025353021,"author":{"id":"3573693462129192","authorId":"3573693462129192","name":"WilliamWCW","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573693462129192","authorIdStr":"3573693462129192"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168300830","repostId":"1103057922","repostType":2,"repost":{"id":"1103057922","kind":"news","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company <b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8 <a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
